A research-based pharmaceutical company | Eisai US
Oct 31, 2024 · Eisai is a research-based human health care company that discovers, develops and markets phamaceutical products internationally. Learn more about Eisai today.
Eisai Co., Ltd.｜A human health care company
EISAI PRESENTS LATEST CLINICAL FINDINGS SUGGESTING INHIBITION OF TAU PROPAGATION BY ANTI-MTBR TAU ANTIBODY E2814 AT THE 17TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE CONFERENCE (CTAD) Eisai Initiates Phase II Clinical Study on Sporadic Early Alzheimer's Disease. October 30, 2024.
Eisai (company) - Wikipedia
Eisai Co., Ltd. (Japanese: エーザイ株式会社, Hepburn: Ēzai Kabushiki-gaisha) is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research. Eisai is listed on the Tokyo Stock Exchange and is a member of the Topix 100 and Nikkei 225 stock indices. [3]
Eisai at a Glance | About Eisai - Eisai Co., Ltd.
Eisai at a Glance. A Leading Global Research and Development-Based Pharmaceutical Company Headquartered in Japan. Established in 1941, Eisai is a pharmaceutical company operating globally in terms of R&D, manufacturing and marketing, with a …
Pharmaceutical oncology and neurology products | Eisai US
We work tirelessly to discover and develop products that give patients and their families the strength to keep fighting. Learn more about our solutions today.
Who we are as a medical solutions company | Eisai US
Eisai came to America in 1987 with one goal in mind: Create innovative new medicines to help patients, their families and caregivers. We’ve been breaking through ever since, with solutions and therapies that help improve the lives of the people we serve.
News Release：2024 | Eisai Co., Ltd.
Oct 30, 2024 · eisai commences business activities at new pharma sales subsidiary in israel. january 18, 2023. eisai listed as a global 100 most sustainable corporation for the seventh time highest ranked global pharmaceutical company. january 18, 2023. eisai aims to advance gastrointestinal cancer treatment with research across multiple tumor types at asco ...
Eisai US - LinkedIn
Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases).
Eisai, Biogen get U.S. FDA approval for Alzheimer's drug, apply for ...
Jan 6, 2023 · Jan 7 (Reuters) - The U.S. Food and Drug Administration on Friday approved the Alzheimer's drug lecanemab developed by Eisai Co Ltd (4523.T) and Biogen Inc (BIIB.O) for patients in the earliest...
Eisai Receives Positive Opinion from the CHMP in the European …
1 day ago · Eisai serves as the lead for lecanemab's development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision ...